Renal effects of immune checkpoint inhibitors

被引：74

作者：

Izzedine, Hassan ^{[1
]}

Mateus, Christine ^{[2
]}

Boutros, Celine ^{[2
]}

Robert, Caroline ^{[2
]}

Rouvier, Philippe ^{[3
]}

Amoura, Zahir ^{[4
]}

Mathian, Alexis

机构：

[1] Monceau Pk Int Clin Paris, Dept Nephrol, Paris, France

[2] Gustave Roussy Inst, Dept Oncol, Villejuif, France

[3] Hop La Pitie Salpetriere, Dept Pathol, Paris, France

[4] Hop La Pitie Salpetriere, Dept Internal Med 2, Paris, France

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2017年 / 32卷 / 06期

关键词：

checkpoint blockade; immunotherapy; ipilimumab; nivolumab; pembrolizumab; OVERCOMING IMMUNOLOGICAL-TOLERANCE; ACUTE INTERSTITIAL NEPHRITIS; MELANOMA TARGETING CTLA-4; ANTI-PD-1; ANTIBODY; PHASE-II; IPILIMUMAB; NIVOLUMAB; SAFETY; BLOCKADE; PEMBROLIZUMAB;

D O I：

10.1093/ndt/gfw382

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

Recent advances in immune checkpoint inhibitor (ICPI) development have led to major improvements in oncology patient outcomes. Cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) are two essential immune checkpoint receptors. Ipilimumab and tremelimumab (anti-CTLA-4-blocking antibodies) and pembrolizumab and nivolumab (antibodies targeting PD-1 receptors) have already been approved by US Food and Drug Administration in several malignancies. Two different forms of ICPI-induced renal damage have been identified, including acute (granulomatous) tubulointerstitial nephritis and immune complex glomerulonephritis. The observed acute renal damage can be reversed upon ICPI drug discontinuation and renal function can recover back to normal following the introduction of systemic corticosteroid treatment. Any delay in treating this complication could result in definitive and irreversible renal injury.

引用

页码：936 / 942

页数：7

共 72 条

[51] Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial [J].

Robert, Caroline ;

Ribas, Antoni ;

Wolchok, Jedd D. ;

Hodi, F. Stephen ;

Hamid, Omid ;

Kefford, Richard ;

Weber, Jeffrey S. ;

Joshua, Anthony M. ;

Hwu, Wen-Jen ;

Gangadhar, Tara C. ;

Patnaik, Amita ;

Dronca, Roxana ;

Zarour, Hassane ;

Joseph, Richard W. ;

Boasberg, Peter ;

Chmielowski, Bartosz ;

Mateus, Christine ;

Postow, Michael A. ;

Gergich, Kevin ;

Elassaiss-Schaap, Jeroen ;

Li, Xiaoyun Nicole ;

Iannone, Robert ;

Ebbinghaus, Scot W. ;

Kang, S. Peter ;

Daud, Adil .

LANCET, 2014, 384 (9948) :1109-1117

[52] Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control [J].

Robert, Caroline ;

Schadendorf, Dirk ;

Messina, Marianne ;

Hodi, F. Stephen ;

O'Day, Steven .

CLINICAL CANCER RESEARCH, 2013, 19 (08) :2232-2239

[53] Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma [J].

Robert, Caroline ;

Thomas, Luc ;

Bondarenko, Igor ;

O'Day, Steven ;

Weber, Jeffrey ;

Garbe, Claus ;

Lebbe, Celeste ;

Baurain, Jean-Francois ;

Testori, Alessandro ;

Grob, Jean-Jacques ;

Davidson, Neville ;

Richards, Jon ;

Maio, Michele ;

Hauschild, Axel ;

Miller, Wilson H., Jr. ;

Gascon, Pere ;

Lotem, Michal ;

Harmankaya, Kaan ;

Ibrahim, Ramy ;

Francis, Stephen ;

Chen, Tai-Tsang ;

Humphrey, Rachel ;

Hoos, Axel ;

Wolchok, Jedd D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2517-2526

[54] OBSERVATIONS ON THE SYSTEMIC ADMINISTRATION OF AUTOLOGOUS LYMPHOKINE-ACTIVATED KILLER CELLS AND RECOMBINANT INTERLEUKIN-2 TO PATIENTS WITH METASTATIC CANCER [J].

ROSENBERG, SA ;

LOTZE, MT ;

MUUL, LM ;

LEITMAN, S ;

CHANG, AE ;

ETTINGHAUSEN, SE ;

MATORY, YL ;

SKIBBER, JM ;

SHILONI, E ;

VETTO, JT ;

SEIPP, CA ;

SIMPSON, C ;

REICHERT, CM .

NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (23) :1485-1492

[55] Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma [J].

Schadendorf, Dirk ;

Hodi, F. Stephen ;

Robert, Caroline ;

Weber, Jeffrey S. ;

Margolin, Kim ;

Hamid, Omid ;

Patt, Debra ;

Chen, Tai-Tsang ;

Berman, David M. ;

Wolchok, Jedd D. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) :1889-U48

[56] Reversal of the TCR stop signal by CTLA-4 [J].

Schneider, Helga ;

Downey, Jos ;

Smith, Andrew ;

Zinselmeyer, Bernd H. ;

Rush, Catherine ;

Brewer, James M. ;

Bin Wei ;

Hogg, Nancy ;

Garside, Paul ;

Rudd, Christopher E. .

SCIENCE, 2006, 313 (5795) :1972-1975

[57] Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients [J].

Shirali, Anushree C. ;

Perazella, Mark A. ;

Gettinger, Scott .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2016, 68 (02) :287-291

[58]

Squibb Bristol-Myers, 2013, YERVOY IPILIMUMAB PA

[59] LOSS OF CTLA-4 LEADS TO MASSIVE LYMPHOPROLIFERATION AND FATAL MULTIORGAN TISSUE DESTRUCTION, REVEALING A CRITICAL NEGATIVE REGULATORY ROLE OF CTLA-4 [J].

TIVOL, EA ;

BORRIELLO, F ;

SCHWEITZER, AN ;

LYNCH, WP ;

BLUESTONE, JA ;

SHARPE, AH .

IMMUNITY, 1995, 3 (05) :541-547

[60] Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy [J].

Topalian, Suzanne L. ;

Drake, Charles G. ;

Pardoll, Drew M. .

CANCER CELL, 2015, 27 (04) :450-461

← 1 2 3 4 5 6 7 8 →